Onesource Specialty Pharma
1,830.50
-16.10(-0.87%)
Market Cap₹21,148.20 Cr
PE Ratio-1,667.00
IndustryHealthcare
Company Performance:
1D-0.87%
1M-0.27%
6M+16.99%
1Y+7.05%
5Y+7.05%
View Company Insightsright
More news about Onesource Specialty Pharma
10Apr 25
OneSource Specialty Pharma's Unit 2 Secures ANVISA GMP Certification, Expanding Market Reach to Brazil
OneSource Specialty Pharma's Unit 2 in Bengaluru has obtained GMP certification from ANVISA, Brazil's Health Regulatory Agency, following a November 2024 inspection. This approval allows the company to supply Drug-Device Combinations and GLP-1s to the Brazilian market, subject to product approvals. The certification is particularly significant as Brazil is expected to be a major market for generic Semaglutide in 2026. OneSource, formerly Stelis Biopharma, is an Indian specialty pharma CDMO with five globally approved facilities.
07Mar 25
SEBI Guidance Halts OneSource Specialty Pharma's QIP Plans Post-Listing
OneSource Specialty Pharma, a newly listed pharmaceutical company, faces a setback in its capital raising plans due to SEBI guidance. The company is prohibited from conducting a Qualified Institutional Placement (QIP) immediately after listing, owing to its involvement in a merger with an unlisted entity prior to going public. SEBI mandates a one-year waiting period post-listing before OneSource can initiate a QIP. This delay may impact the company's short-term growth strategies and force it to seek alternative funding sources.
Onesource Specialty Pharma
1,830.50
-16.10
(-0.87%)
1 Year Returns:+7.05%
Industry Peers
Sun Pharmaceutical
1,679.10
(+1.21%)
Divis Laboratories
6,621.50
(+0.32%)
Cipla
1,577.60
(+0.52%)
Torrent Pharmaceuticals
3,584.30
(+1.43%)
Dr Reddys Laboratories
1,255.90
(+1.27%)
Mankind Pharma
2,476.60
(+0.87%)
Zydus Life Science
987.65
(+0.31%)
Lupin
1,940.00
(-0.57%)
Alkem Laboratories
5,581.50
(+1.04%)
Aurobindo Pharma
1,101.00
(-0.48%)